Tag Archives: clinical trials

Soaring stocks and the reasons why (LLTC, UEPS, CBRX)

Posted on January 18, 2012 by Cameron White

In this report: Columbia Laboratories (NASDAQ:CBRX), Net 1 UEPS Technologies (NASDAQ:UEPS) and Linear Technology Corp. (NASDAQ:LLTC).

Columbia Laboratories (NASDAQ:CBRX) shares are rebounding today after seeing a more than 56 percent drop yesterday. The selloff came after reviewers from the Food …

Posted in Latest Headlines, Reports | Tagged Analysts, cash paymaster services, CBRX, clinical trials, Columbia Laboratories, earnings, FDA, Food and Drug Administration, forecast, Linear Technology Corp., LLTC, NASDAQ, NASDAQ:CBRX, NASDAQ:LLTC, NASDAQ:UEPS, Net 1 UEPS Technologies, net income, predicted, quarter, report, revenue, SASSA, selloff, share, shars, stock, UEPS | Comments Off

Tuesday’s big time losers and the reasons why (CBRX, SAVE, KGC)

Posted on January 17, 2012 by Martin Timble

In this report: Kinross Gold (NYSE:KGC), Columbia Laboratories (NASDAQ:CBRX) and Sprint Airlines (NASDAQ:SAVE).

Columbia Laboratories (NASDAQ:CBRX) shares have sank by more than 56 percent so far today after reviewers from the Food and Drug Administration said that the company’s gel …

Posted in Latest Headlines, Reports | Tagged advisory panel, Africa, CBRX, clinical trials, Columbia Laboratories, common stock, Construction, costs, expenses, FDA, Food and Drug Administration, Gold, KGC, Kinross Gold, NASDAQ, NASDAQ:CBRX, NASDAQ:SAVE, NYSE, NYSE:KGC, operating, ounces, productions, risk, save, secondary offering, shareholders, shares, Sprint Airlines | Comments Off

What’s up Akorn, Pharmasset and Corinthian Colleges?

Posted on November 1, 2011 by Cameron White

In this report: Akorn Inc. (NASDAQ:AKRX), Pharmasset Inc. (NASDAQ:VRUS) and Corinthian Colleges (NASDAQ:COCO).

Akorn Inc. (NASDAQ:AKRX) has gained more than 11 percent today after the company reported a record third quarter. The company reported revenue of $36.7 million, up 69 …

Posted in Latest Headlines, Reports | Tagged 2012, adjusted, Akorn Inc., AKRX, Analysts, clinical trials, COCO, company, Corinthian Colleges, drug, earnings, EBITDA, experimental, fiscal, full-year, hepatitis C, late stage, marketing approval, NASDAQ:AKRX, NASDAQ:COCO, NASDAQ:VRUS, net income, outlook, Pharmasset Inc., predicted, profits, quarter, reported, results, revenue, ribavirin, trades, VRUS, Wall Street | Comments Off

4 stocks to watch (PNM, MNKD, YOKU, RDS-A)

Posted on September 23, 2011 by pmarek

In this report: PNM Resources (NYSE:PNM), MannKind Corp. (NASDAQ:MNKD), Royal Dutch Shell (NYSE:RDS-A) and Youku.com Inc. (NYSE:YOKU).

PNM Resources (NYSE:PNM) is trading more than 16.9 percent higher today after the company announced that it will sell its competitive business in …

Posted in Latest Headlines | Tagged Afrezza, analyst, Analysts, Benchmark comapny, business, capital, cash, clinical trials, company, deal, diabetes, Direct Energy, drug, earnings, firm, First Choice, forecast, Hold, insulin, MannKind Corp., MNKD, NASDAQ, NASDAQ:MNKD, Neutral, notes, NYSE, NYSE:PNM, NYSE:RDS-A, NYSE:YOKU, outlook, patients, PNM, PNM Resources, positive, Power Business, profitibility, profits, raise, rating, Royal Dutch Shell, sell, senior secured, stock, Susquehanna, trading, utilities, working capital, YOKU, Youku.com Inc. | Comments Off

End of week market report (IDCC, PPHM, PGIE)

Posted on September 2, 2011 by Josie Middleton

In this report: Peregrine Pharmaceuticals (NASDAQ:PPHM), PGI Energy (PINK:PGIE) and InterDigital (NASDAQ:IDCC)

Peregrine Pharmaceuticals (NASDAQ:PPHM) is trading 7.3 percent lower today following its announcement that it has agreed the sale of an aggregate of 6,252,252 shares of common stock to …

Posted in Latest Headlines | Tagged AAPL, Apple, capital, clinical trials, common stock, COMPANIES, company, convertible, corporate, deal, dilution, dividend, gained, IDCC, InterDigital, investors, issuance, management, NASDAQ, NASDAQ:AAPL, NASDAQ:IDCC, NASDAQ:PPHM, NASDAQ:QCOM, NOK, Nokia, NYSE:NOK, offering, patent, patents, Peregrine Pharmaceuticals, PGI Energy, PGIE, PINK:PGIE, PPHM, preffered shares, QCOM, Qualcomm, research and development, restricted, sale, shareholders, stock, takeover bid, tech, trades, trading, war | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.